{"transactions":[{"id":4629996,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32184,"kind":"person","name":"Cobo Marc","position":1,"cik":"0001816654","reported_name":"Cobo Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-10-05T20:14:39.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":126,"price":3.94,"value":496.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":14015,"source":{"system":"sec-edgar","filing":"0001193125-26-414135","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526414135/ownership.xml","form_type":"4"}},{"id":4629992,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32182,"kind":"person","name":"Elmelech Idan","position":1,"cik":"0002058437","reported_name":"Elmelech Idan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Principal Financial Ofcr"}}],"security":"Common Stock","published_at":"2026-10-05T20:13:56.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":343,"price":3.94,"value":1351.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":14152,"source":{"system":"sec-edgar","filing":"0001193125-26-414131","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2058437/000119312526414131/ownership.xml","form_type":"4"}},{"id":4629977,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-10-05T20:12:46.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1047,"price":3.94,"value":4125.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":43529,"source":{"system":"sec-edgar","filing":"0001193125-26-414127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2058152/000119312526414127/ownership.xml","form_type":"4"}},{"id":4629960,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32204,"kind":"person","name":"Ben Yong","position":1,"cik":"0001967669","reported_name":"Ben Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med & Dev Officer"}}],"security":"Common Stock","published_at":"2026-10-05T20:11:29.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1047,"price":3.94,"value":4125.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":43529,"source":{"system":"sec-edgar","filing":"0001193125-26-414123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967669/000119312526414123/ownership.xml","form_type":"4"}},{"id":4616964,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32184,"kind":"person","name":"Cobo Marc","position":1,"cik":"0001816654","reported_name":"Cobo Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-14T20:24:02.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":43700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":43700,"derivative":{"exercise_price":5.52,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":43700},"source":{"system":"sec-edgar","filing":"0001193125-26-390624","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526390624/ownership.xml","form_type":"4"}},{"id":4616963,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32184,"kind":"person","name":"Cobo Marc","position":1,"cik":"0001816654","reported_name":"Cobo Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:24:02.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":203,"price":5.52,"value":1120.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":14141,"source":{"system":"sec-edgar","filing":"0001193125-26-390624","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526390624/ownership.xml","form_type":"4"}},{"id":4616962,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32184,"kind":"person","name":"Cobo Marc","position":1,"cik":"0001816654","reported_name":"Cobo Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:24:02.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":9038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from April 21, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting."}],"balance_after":14344,"source":{"system":"sec-edgar","filing":"0001193125-26-390624","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526390624/ownership.xml","form_type":"4"}},{"id":715546,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32184,"kind":"person","name":"Cobo Marc","position":1,"cik":"0001816654","reported_name":"Cobo Marc","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-07-06T22:00:07.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":125,"price":7.8,"value":975.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":5306,"source":{"system":"sec-edgar","filing":"0001193125-26-296504","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526296504/ownership.xml","form_type":"4"}},{"id":715544,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32182,"kind":"person","name":"Elmelech Idan","position":1,"cik":"0002058437","reported_name":"Elmelech Idan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Principal Financial Ofcr"}}],"security":"Common Stock","published_at":"2026-07-06T22:00:06.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":343,"price":7.8,"value":2675.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":14495,"source":{"system":"sec-edgar","filing":"0001193125-26-296503","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526296503/ownership.xml","form_type":"4"}},{"id":715653,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32204,"kind":"person","name":"Ben Yong","position":1,"cik":"0001967669","reported_name":"Ben Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med & Dev Officer"}}],"security":"Common Stock","published_at":"2026-07-06T22:00:04.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1047,"price":7.8,"value":8166.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":44576,"source":{"system":"sec-edgar","filing":"0001193125-26-296502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967669/000119312526296502/ownership.xml","form_type":"4"}},{"id":715545,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-06T22:00:03.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1047,"price":7.8,"value":8166.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":44576,"source":{"system":"sec-edgar","filing":"0001193125-26-296501","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526296501/ownership.xml","form_type":"4"}},{"id":715543,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":130865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Master Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Cormorant Global Healthcare Master Fund, LP (\"Master Fund\"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":6083221,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":715542,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":1704862,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Fund V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Cormorant Private Healthcare Fund V, LP (\"Fund V\"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":5010332,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":715541,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":2692459,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Fund III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Cormorant Private Healthcare Fund III, LP (\"Fund III\"), which is an investment vehicle managed by Cormorant Asset Management, LP (\"CAM\"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4879995,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":715540,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T20:34:53.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":false,"shares":4528186,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Helix Holdings II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution to the members of Helix Holdings II LLC (the \"Sponsor\") for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-26-075538","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390026075538/ownership.xml","form_type":"4"}},{"id":732287,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36852,"kind":"person","name":"Tipirneni Praveen P.","position":1,"cik":"0001779978","reported_name":"Tipirneni Praveen P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:59:27.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276050","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276050/ownership.xml","form_type":"4"}},{"id":732286,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":35664,"kind":"person","name":"MCCORMICK FRANK","position":1,"cik":"0001257809","reported_name":"MCCORMICK FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:58:36.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276048/ownership.xml","form_type":"4"}},{"id":732285,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36851,"kind":"person","name":"Lebowitz Peter F","position":1,"cik":"0002121402","reported_name":"Lebowitz Peter F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:57:26.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":7289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":7289,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":7289},"source":{"system":"sec-edgar","filing":"0001193125-26-276046","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276046/ownership.xml","form_type":"4"}},{"id":732283,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36850,"kind":"person","name":"Kelleher Raymond J.","position":1,"cik":"0002058193","reported_name":"Kelleher Raymond J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:56:35.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276043","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276043/ownership.xml","form_type":"4"}},{"id":732284,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:55:36.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276041","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276041/ownership.xml","form_type":"4"}},{"id":732282,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36849,"kind":"person","name":"Bauer Jake","position":1,"cik":"0001654909","reported_name":"Bauer Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:54:30.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276035/ownership.xml","form_type":"4"}},{"id":732281,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":21251,"kind":"person","name":"Kumar Neil","position":1,"cik":"0001742485","reported_name":"Kumar Neil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:53:23.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":31675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":31675,"derivative":{"exercise_price":7.73,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":31675},"source":{"system":"sec-edgar","filing":"0001193125-26-276033","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526276033/ownership.xml","form_type":"4"}},{"id":782679,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32182,"kind":"person","name":"Elmelech Idan","position":1,"cik":"0002058437","reported_name":"Elmelech Idan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Principal Financial Ofcr"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-12T20:12:24.000Z","date":"2026-05-10","kind":"grant","planned":false,"acquired":true,"shares":758222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":758222,"derivative":{"exercise_price":7.66,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":758222},"source":{"system":"sec-edgar","filing":"0001193125-26-219447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526219447/ownership.xml","form_type":"4"}},{"id":782678,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-12T20:11:42.000Z","date":"2026-05-10","kind":"grant","planned":false,"acquired":true,"shares":1103837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":1103837,"derivative":{"exercise_price":7.66,"expiration_date":"2036-05-09","underlying":"Common Stock","underlying_shares":1103837},"source":{"system":"sec-edgar","filing":"0001193125-26-219439","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526219439/ownership.xml","form_type":"4"}},{"id":792028,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32204,"kind":"person","name":"Ben Yong","position":1,"cik":"0001967669","reported_name":"Ben Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med & Dev Officer"}}],"security":"Common Stock","published_at":"2026-05-05T23:05:35.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1047,"price":9.03,"value":9454.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":45623,"source":{"system":"sec-edgar","filing":"0001193125-26-207041","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967669/000119312526207041/ownership.xml","form_type":"4"}},{"id":791911,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-05T23:03:26.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1047,"price":9.03,"value":9454.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":45623,"source":{"system":"sec-edgar","filing":"0001193125-26-207035","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526207035/ownership.xml","form_type":"4"}},{"id":791955,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer"}}],"security":"Common Stock","published_at":"2026-05-05T23:01:37.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":524,"price":9.03,"value":4731.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":22806,"source":{"system":"sec-edgar","filing":"0001193125-26-207031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000119312526207031/ownership.xml","form_type":"4"}},{"id":827451,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36851,"kind":"person","name":"Lebowitz Peter F","position":1,"cik":"0002121402","reported_name":"Lebowitz Peter F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-26T21:14:24.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":63350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 24, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":63350,"derivative":{"exercise_price":8.72,"expiration_date":"2036-03-23","underlying":"Common Stock","underlying_shares":63350},"source":{"system":"sec-edgar","filing":"0001193125-26-126602","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526126602/ownership.xml","form_type":"4"}},{"id":846445,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T20:58:25.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":105000,"derivative":{"exercise_price":10.19,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001193125-26-104384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000119312526104384/ownership.xml","form_type":"4"}},{"id":846444,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-12T20:58:25.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":23330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting."}],"balance_after":23330,"source":{"system":"sec-edgar","filing":"0001193125-26-104384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000119312526104384/ownership.xml","form_type":"4"}},{"id":846409,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T20:57:30.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":210000,"derivative":{"exercise_price":10.19,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001193125-26-104379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526104379/ownership.xml","form_type":"4"}},{"id":846408,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-12T20:57:30.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":46670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting."}],"balance_after":46670,"source":{"system":"sec-edgar","filing":"0001193125-26-104379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526104379/ownership.xml","form_type":"4"}},{"id":846494,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32204,"kind":"person","name":"Ben Yong","position":1,"cik":"0001967669","reported_name":"Ben Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med & Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T20:56:14.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":210000,"derivative":{"exercise_price":10.19,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001193125-26-104369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1967669/000119312526104369/ownership.xml","form_type":"4"}},{"id":846493,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32204,"kind":"person","name":"Ben Yong","position":1,"cik":"0001967669","reported_name":"Ben Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med & Dev Officer"}}],"security":"Common Stock","published_at":"2026-03-12T20:56:14.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":46670,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting."}],"balance_after":46670,"source":{"system":"sec-edgar","filing":"0001193125-26-104369","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967669/000119312526104369/ownership.xml","form_type":"4"}},{"id":951927,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":70354,"kind":"person","name":"Wallace Eli M.","position":1,"cik":"0001776352","reported_name":"Wallace Eli M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T00:22:35.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":1114400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"69,650 of the shares underlying the option vested on January 2, 2026. Thereafter, 1/48th of the shares underlying the option will vest monthly, with full vesting scheduled for October 2, 2029, subject to the Reporting Person's continuous service with the Issuer on each such vesting date."}],"balance_after":1114400,"derivative":{"exercise_price":12.52,"expiration_date":"2035-12-31","underlying":"Common Stock","underlying_shares":1114400},"source":{"system":"sec-edgar","filing":"0001193125-26-003027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526003027/ownership.xml","form_type":"4"}},{"id":971394,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":70354,"kind":"person","name":"Wallace Eli M.","position":1,"cik":"0001776352","reported_name":"Wallace Eli M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-13T00:04:11.000Z","date":"2025-12-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1114400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 10, 2025, the Issuer rescinded 1,114,400 stock options that were part of the Reporting Person's option grant dated October 2, 2025 (the \"Rescinded Portion\"). The Rescinded Portion was cancelled and the remaining 500,000 stock options from the original grant continue to remain outstanding. The rescission was an exempt disposition to the Issuer per Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":500000,"derivative":{"exercise_price":12.44,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":1114400},"source":{"system":"sec-edgar","filing":"0001193125-25-317962","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312525317962/ownership.xml","form_type":"4"}},{"id":1017747,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":74218,"kind":"organization","name":"BridgeBio Pharma LLC","position":1,"cik":"0002076615","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":2,"cik":"0001743881","reported_name":"BridgeBio Pharma, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-16T17:54:33.000Z","date":"2025-10-10","kind":"other","planned":false,"acquired":true,"shares":784720,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by BridgeBio Pharma LLC (\"BBIO LLC\"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. (\"BBIO\"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the \"BBIO Directors\"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"(Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14589846,"source":{"system":"sec-edgar","filing":"0001193125-25-241634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2076615/000119312525241634/ownership.xml","form_type":"4"}},{"id":1023443,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":70354,"kind":"person","name":"Wallace Eli M.","position":1,"cik":"0001776352","reported_name":"Wallace Eli M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-06T20:22:15.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":1614400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":1614400,"derivative":{"exercise_price":12.44,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":1614400},"source":{"system":"sec-edgar","filing":"0001193125-25-231917","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312525231917/ownership.xml","form_type":"4"}},{"id":1053716,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36852,"kind":"person","name":"Tipirneni Praveen P.","position":1,"cik":"0001779978","reported_name":"Tipirneni Praveen P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:44:27.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":52269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 (\"Vesting Commencement Date\") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the \"S-8 Filing Date\") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":52269,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":52269},"source":{"system":"sec-edgar","filing":"0000950170-25-112020","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000095017025112020/ownership.xml","form_type":"4"}},{"id":1053715,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":35664,"kind":"person","name":"MCCORMICK FRANK","position":1,"cik":"0001257809","reported_name":"MCCORMICK FRANK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:43:27.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":91076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 (\"Vesting Commencement Date\") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the \"S-8 Filing Date\") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":91076,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":91076},"source":{"system":"sec-edgar","filing":"0000950170-25-112016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000095017025112016/ownership.xml","form_type":"4"}},{"id":1053717,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":36849,"kind":"person","name":"Bauer Jake","position":1,"cik":"0001654909","reported_name":"Bauer Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:41:23.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":138193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A fraction of the shares underlying such option equal to (x) the number of full months between April 25, 2025 (\"Vesting Commencement Date\") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the \"S-8 Filing Date\") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":138193,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":138193},"source":{"system":"sec-edgar","filing":"0000950170-25-112008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000095017025112008/ownership.xml","form_type":"4"}},{"id":1053713,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32183,"kind":"person","name":"Beltran Pedro","position":1,"cik":"0002058152","reported_name":"Beltran Pedro","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:39:42.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":357177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 (\"Vesting Commencement Date\") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the \"S-8 Filing Date\") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":357177,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":357177},"source":{"system":"sec-edgar","filing":"0000950170-25-112003","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000095017025112003/ownership.xml","form_type":"4"}},{"id":1053751,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":32204,"kind":"person","name":"Ben Yong","position":1,"cik":"0001967669","reported_name":"Ben Yong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Med & Dev Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:37:59.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":357177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 (\"Vesting Commencement Date\") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the \"S-8 Filing Date\") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":357177,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":357177},"source":{"system":"sec-edgar","filing":"0000950170-25-111997","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1967669/000095017025111997/ownership.xml","form_type":"4"}},{"id":1053712,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":70354,"kind":"person","name":"Wallace Eli M.","position":1,"cik":"0001776352","reported_name":"Wallace Eli M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:36:16.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":499731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"A fraction of the shares underlying such option equal to (x) the number of full months between August 11, 2025 (\"Vesting Commencement Date\") and the date on which a registration statement on Form S-8 is filed and effective with the Securities and Exchange Commission (the \"S-8 Filing Date\") divided by (y) 48 shall vest on the S-8 Filing Date, and 1/48th of the shares underlying such option shall vest each month thereafter on the day of the month corresponding to the Vesting Commencement Date (and if there is no suchcorresponding day for a month, then the vesting date shall be the last day of the applicable month) until 100% of the shares underlying such option is vested on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":499731,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":499731},"source":{"system":"sec-edgar","filing":"0000950170-25-111992","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000095017025111992/ownership.xml","form_type":"4"}},{"id":1053737,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:34:54.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":633570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying such option shall vest on July 21, 2026, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":633570,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":633570},"source":{"system":"sec-edgar","filing":"0000950170-25-111986","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000095017025111986/ownership.xml","form_type":"4"}},{"id":1067921,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B ordinary shares","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":4172126,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":4172126},"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067920,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B ordinary shares","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":307874,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination (the \"Business Combination\") between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc. (\"Legacy BBOT\"), Helix Holdings II LLC (the \"Sponsor\") forfeited 307,874 Helix Class B ordinary shares for no consideration pursuant to the terms of the Sponsor Support Agreement dated February 28, 2025, between Sponsor, Helix, and Legacy BBOT (the \"Sponsor Support Agreement\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Helix Class B ordinary shares have no expiration date and automatically convert into Class A ordinary shares at the time of Helix's initial business combination as described under the heading \"Description of Securities\" in Helix's registration statement on Form S-1 (File No. 333-276591)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":4172126,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":307874},"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067919,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":284571,"ownership":{"direct":false,"nature":"Via Master Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":5952356,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067918,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":1762760,"ownership":{"direct":false,"nature":"Via Fund V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":3305470,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067917,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":1905046,"ownership":{"direct":false,"nature":"Via Fund IV"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Upon the closing of the Business Combination, as contemplated by the terms of the Business Combination Agreement, dated as of February 28, 2025 (as amended, the \"Business Combination Agreement\"), by and among Helix, Legacy BBOT, and Helix Merger Sub, Inc., the owners of Legacy BBOT equity as of immediately prior to the closing, including Fund V, Master Fund, and Cormorant Private Healthcare Fund IV, LP (\"Fund IV\"), received as consideration therefor, shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":1905046,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067916,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":5598425,"price":10.7173,"value":60000000.2525,"ownership":{"direct":false,"nature":"Via Master Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Global Healthcare Master Fund, LP (\"Master Fund\"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 5,598,425 shares of Common Stock at a purchase price of $10.7173 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":5667785,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067915,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":639110,"price":10.7173,"value":6849533.603,"ownership":{"direct":false,"nature":"Via Fund V"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of the Subscription Agreement, Cormorant Private Healthcare Fund V, LP (\"Fund V\"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 639,110 shares of Common Stock at a purchase price of $10.7173 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":1542710,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067914,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":760496,"price":10.7173,"value":8150463.7808,"ownership":{"direct":false,"nature":"Via Fund III"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with and immediately prior to the closing of the Business Combination, pursuant to the terms of a subscription agreement dated February 28, 2025 between Helix and Cormorant Asset Management, LP (the \"Subscription Agreement\"), Cormorant Private Healthcare Fund III, LP (\"Fund III\"), which is an investment vehicle managed by Cormorant Asset Management, LP, purchased from the Issuer 760,496 shares of Common Stock at a purchase price of $10.7173 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Cormorant Asset Management, LP serves as the investment manager to Fund III, Fund IV, Fund V, and Master Fund (collectively, the \"Cormorant Funds\"). Cormorant Private Healthcare GP III, LLC (\"GP III\") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC (\"GP IV\") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC (\"GP V\") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC (\"Global GP\") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of Cormorant Asset Management, LP. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and Cormorant Asset Management, LP. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":2187536,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067913,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":152940,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Via Helix Holdings II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"In connection with and immediately prior to the closing of the Business Combination, the Sponsor forfeited 152,940 shares of Common Stock for no consideration, pursuant to the terms of the Sponsor Support Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":4528186,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1067912,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-13T12:28:26.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":4172126,"ownership":{"direct":false,"nature":"Via Helix Holdings II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with and prior to the closing of the Business Combination, among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), on a one-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly."}],"balance_after":4681126,"source":{"system":"sec-edgar","filing":"0001213900-25-075305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025075305/ownership.xml","form_type":"4"}},{"id":1070334,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B ordinary shares","published_at":"2025-08-11T21:01:51.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-074368","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074368/ownership.xml","form_type":"4"}},{"id":1070333,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2025-08-11T21:01:51.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-25-074368","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074368/ownership.xml","form_type":"4"}},{"id":1070332,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B ordinary shares","published_at":"2025-08-11T21:00:11.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-074364","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074364/ownership.xml","form_type":"4"}},{"id":1070331,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25051,"kind":"person","name":"Schmid John P.","position":1,"cik":"0001478916","reported_name":"Schmid John P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2025-08-11T21:00:11.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-25-074364","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025074364/ownership.xml","form_type":"4"}},{"id":1070532,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":76723,"kind":"person","name":"Holman Albert A III","position":1,"cik":"0002056154","reported_name":"Holman Albert A III","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B ordinary shares","published_at":"2025-08-11T17:04:12.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Class A ordinary shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-074375","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056154/000121390025074375/ownership.xml","form_type":"4"}},{"id":1070531,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":76723,"kind":"person","name":"Holman Albert A III","position":1,"cik":"0002056154","reported_name":"Holman Albert A III","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2025-08-11T17:04:12.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, \"Helix\") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading \"Description of Securities\" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the \"Domestication\"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-25-074375","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056154/000121390025074375/ownership.xml","form_type":"4"}},{"id":1276752,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class B Ordinary Shares","published_at":"2025-02-10T22:06:42.000Z","date":"2025-02-08","kind":"other","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B ordinary shares will automatically convertible into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 8, 2025, Helix Holdings II LLC (the \"Sponsor\") transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B ordinary shares will automatically convertible into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B ordinary shares will automatically convertible into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Sponsor is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of the Sponsor. Bihua Chen is the manager of the Sponsor and is the managing member of each of the three members of the Sponsor and has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Ms. Chen disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4480000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-011810","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025011810/ownership.xml","form_type":"4"}},{"id":1276753,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":83408,"kind":"person","name":"Helix Holdings II LLC","position":1,"cik":"0001869101","reported_name":"Helix Holdings II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2025-02-10T17:07:46.000Z","date":"2025-02-08","kind":"other","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":". The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 8, 2025, the Reporting Person transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":". The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":". The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading \"Description of Securities--Founder Shares and Private Placement Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Person is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of the Reporting Person and is the managing member of each of the three members of the Reporting Person and has voting and investment discretion with respect to the ordinary shares held of record by Reporting Person. Ms. Chen disclaims any beneficial ownership of the securities held by the Reporting Person other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":4480000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001213900-25-011813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869101/000121390025011813/ownership.xml","form_type":"4"}},{"id":1646543,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":903600,"price":10,"value":9036000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Cormorant Private Healthcare Fund V, LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Private Healthcare Fund V, LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Private Healthcare Fund V, LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":903600,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646542,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":1427040,"price":10,"value":14270400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Cormorant Private Healthcare Fund III, LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Private Healthcare Fund III, LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Private Healthcare Fund III, LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":1427040,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646541,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":69360,"price":10,"value":693600.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Cormorant Global Healthcare Master Fund LP is the record holder of such securities. Ms. Chen is the managing member of Cormorant Global Healthcare Master Fund LP and has voting and investment discretion with respect to the ordinary shares of record held thereby. Ms. Chen disclaims any beneficial ownership of the securities held by Cormorant Global Healthcare Master Fund LP other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":69360,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646540,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":25044,"kind":"person","name":"Chen Bihua","position":1,"cik":"0001599214","reported_name":"Chen Bihua","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and Chairperson"}}],"security":"Class A Ordinary Shares","published_at":"2024-02-14T00:48:00.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":509000,"price":10,"value":5090000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings II LLC is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of Helix Holdings II LLC and is the managing member of each of the three members of Helix Holdings II LLC and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings II LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings II LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":509000,"source":{"system":"sec-edgar","filing":"0001213900-24-013534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869105/000121390024013534/ownership.xml","form_type":"4"}},{"id":1646544,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":83408,"kind":"person","name":"Helix Holdings II LLC","position":1,"cik":"0001869101","reported_name":"Helix Holdings II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-02-13T19:45:30.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":509000,"price":10,"value":5090000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Helix Holdings II LLC is the record holder of the securities reported herein. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the managing members of Helix Holdings II LLC. Bihua Chen is the manager of Helix Holdings II LLC and is the managing member of each of the three members of Helix Holdings II LLC and has voting and investment discretion with respect to the ordinary shares held of record by Helix Holdings II LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings II LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly."}],"balance_after":509000,"source":{"system":"sec-edgar","filing":"0001213900-24-013530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869101/000121390024013530/ownership.xml","form_type":"4"}}]}